News & Events

In response to the rising global demand for innovative and accessible tools in neurodegenerative disease research, Diazyme is excited to unveil a new panel of six blood-based neurological biomarker assays. Developed exclusively for research use, these assays are optimized for use on the DZ-Lite™ i2000, a fully automated chemiluminescence analyzer with very high sensitivities.

This cutting-edge panel reflects Diazyme's commitment to enabling high-throughput, reliable, and cost-effective biomarker testing—an essential step forward aiding research of neurological diseases such as Alzheimer’s disease.

Empowering Research Through Blood-Specific Biomarker Assays

Traditional methods for studying Alzheimer’s disease and other neurodegenerative conditions often depend on cerebrospinal fluid (CSF) analysis or advanced imaging techniques like PET scans. While effective, these methods are clinically valuable, they are also invasive, costly, and not well-suited for large-scale research studies. Diazyme’s innovative neurological biomarker test panel introduces a research-use-only solution for using plasma samples, offering a non-invasive, cost effective high-throughput alternative for neurological marker testing.

Biomarkers Included in the Research Panel:

• Amyloid Beta 40 (Aβ40)
• Amyloid Beta 42 (Aβ42)
• Phosphorylated Tau 181 (pTau-181)
• Phosphorylated Tau 217 (pTau-217)
• Neurofilament Light Chain (NfL)
• Apolipoprotein E4 (APOE4)

The biomarkers included in Diazyme’s panel have been extensively studied for their roles in brain health and age-related neurological conditions. Diazyme’s assays are designed to deliver reliable results using plasma samples, allowing scientists to streamline studies and broaden the reach of neurological biomarkers testing across diverse research settings.

Key Performance Highlights:

• Ultra-sensitive limits of quantification:
• Aβ40: 2.1 pg/mL
• Aβ42: 2.2 pg/mL
• pTau-181: 0.9 pg/mL
• pTau-217: 0.067 pg/mL
• NfL: 2.9 pg/mL
• The APOE4 assay supports genotype differentiation in research settings (homozygote vs. heterozygote).
• Validated for precision, reproducibility, stability, and accuracy across a wide concentration range.

Fully Automated Analysis with the DZ-Lite™ i2000

All six assays are fully optimized for seamless operation on Diazyme’s DZ-Lite™ i2000 analyzer—delivering an easy-to-use, high-throughput platform that empowers clinical researchers to generate robust data efficiently and reproducibly.

A Glimpse into the Future of Neurological Research

This cutting-edge panel represents Diazyme’s continued commitment to providing high-quality tools for translational research in neurological science. By focusing on blood-based assays, Diazyme aims to support scalable and less invasive research methods that may help expand access to important biomarker data across diverse populations.

Stay Tuned

In addition to the panel's presentation, Diazyme is excited to highlight Lead Scientist Dr. Romany Abskharon’s abstract on this innovative biomarker panel, which will be presented at the ADLM 2025 conference. This presentation highlights the scientific foundation of the biomarker panel and marks a significant milestone in the advancement of neurodegenerative disease research—underscoring the panel’s potential to drive meaningful progress in the field.

For Research Use Only. Not for use in diagnostic procedures.